Trial reportPloS one2014
A systems biology approach investigating the effect of probiotics on the vaginal microbiome and host responses in a double blind, placebo-controlled clinical trial of post-menopausal women.
Trial report in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Single-Center Exploratory Study to Evaluate the Effects of the Probiotics L. Rhamnosus GR-1 and L. Reuteri RC-14 on Subjects With Intermediate Nugent Scores
Re-setting the Breast Microbiome to Lower Inflammation and Risk of Cancer.
Who cites it
32 citing papers in PubMed, 72 citations in OpenAlex.
- Sustained effect of LACTIN-V (Lactobacillus crispatus CTV-05) on genital immunology following standard bacterial vaginosis treatment: results from a randomised, placebo-controlled trial.The Lancet. Microbe · 2022Trial
- ProbioticFrontiers in cellular and infection microbiology · 2021Trial
- Effect of oral consumption of capsules containing Lactobacillus paracasei LPC-S01 on the vaginal microbiota of healthy adult women: a randomized, placebo-controlled, double-blind crossover study.FEMS microbiology ecology · 2020Trial
- The influence of probiotics on genital high-risk human papilloma virus clearance and quality of cervical smear: a randomized placebo-controlled trial.BMC women's health · 2019Trial
- Long-term irritable bowel syndrome symptom control with reintroduction of selected FODMAPs.World journal of gastroenterology · 2017Trial
- Adhesion Properties and Pathogen Inhibition of Vaginal-Derived Lactobacilli.Probiotics and antimicrobial proteins · 2025Article
- Health disorders in menopausal women: microbiome alterations, associated problems, and possible treatments.Biomedical engineering online · 2025Review
- Beyond hormones: 3PM approach to vaginal microbiota dynamics in postmenopausal women.The EPMA journal · 2025Review
- The role of microbiota and toll-like receptors in polycystic ovary syndrome: regulatory mechanisms of androgen metabolism.Endocrine connections · 2025Review
- Lactobacillus Genus Complex Probiotic-Induced Changes on the Equine Clitoral Microbiome.Veterinary sciences · 2025Article
- An in silico framework for the rational design of vaginal probiotic therapy.PLoS computational biology · 2025Article
- Vaginal dysbiosis and the potential of vaginal microbiome-directed therapeutics.Frontiers in microbiomes · 2024Review
- The Role of Hydrogen-Peroxide (HAntioxidants (Basel, Switzerland) · 2023Review
- Review
- The right bug in the right place: opportunities for bacterial vaginosis treatment.NPJ biofilms and microbiomes · 2022Review
- Healthy Vaginal Microbiota and Influence of Probiotics Across the Female Life Span.Frontiers in microbiology · 2022Review
- Pro-biomics: Omics Technologies To Unravel the Role of Probiotics in Health and Disease.Advances in nutrition (Bethesda, Md.) · 2021Review
- Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurrence of Bacterial Vaginosis?Antibiotics (Basel, Switzerland) · 2021Review
- Vaginal Probiotics for Reproductive Health and Related Dysbiosis: Systematic Review and Meta-Analysis.Journal of clinical medicine · 2021Review
- Microbiomes other than the gut: inflammaging and age-related diseases.Seminars in immunopathology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
unlabelledA lactobacilli dominated microbiota in most pre and post-menopausal women is an indicator of vaginal health. The objective of this double blinded, placebo-controlled crossover study was to evaluate in 14 post-menopausal women with an intermediate Nugent score, the effect of 3 days of vaginal administration of probiotic L. rhamnosus GR-1 and L. reuteri RC-14 (2.5×109 CFU each) on the microbiota and host response. The probiotic treatment did not result in an improved Nugent score when compared to when placebo. Analysis using 16S rRNA sequencing and metabolomics profiling revealed that the relative abundance of Lactobacillus was increased following probiotic administration as compared to placebo, which was weakly associated with an increase in lactate levels. A decrease in Atopobium was also observed. Analysis of host responses by microarray showed the probiotics had an immune-modulatory response including effects on pattern recognition receptors such as TLR2 while also affecting epithelial barrier function. This is the first study to use an interactomic approach for the study of vaginal probiotic administration in post-menopausal women. It shows that in some cases multifaceted approaches are required to detect the subtle molecular changes induced by the host to instillation of probiotic strains.
trial registrationClinicalTrials.gov NCT02139839.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.